Patent SG-11201909154S-A (SG)
Title: Bispecific antibodies specifically binding to pd1 and lag3
Inventor: CODARRI DEAK LAURA
IPC: C07K16/28
Filed: 2018-04-03
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo OH H ioo im mil ono oimIE (10) International Publication Number WO 2018/185043 Al (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/058382 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17165125.0 05 April 2017 (05.04.2017) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: CODARRI DEAK, Laura; c/o Roche Gly- cart AG, Wagistrasse 10, 8952 Schlieren (CH). FISCH- ER, Jens; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). IMHOF-JUNG, Sabine; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). KLEIN, Christian; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). SEEBER, Stefan; c/o Roche Diag- nostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). WE- BER, Patrick Alexander Aaron; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). (74) Agent: KLOSTERMEYER RAUBER, Doerte; Gren- zacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) GO (54) Title: BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 0 (57) : The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 \" and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these 0 molecules and to methods of using the same.